CROSS-LICENSE AGREEMENTCross-License Agreement • November 8th, 2004 • Medarex Inc • Services-commercial physical & biological research
THIS CROSS-LICENSE AGREEMENT (the “Agreement”) is made as of September 15, 2004 (the “Effective Date”) between Pfizer Inc, a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017, and its Affiliates (“Pfizer”), and Medarex, Inc., a New Jersey corporation with a business address at 707 State Road, Princeton, New Jersey 08540 (“Medarex”). Pfizer and Medarex each may be referred to herein individually as a “Party” or collectively as the “Parties.”
LICENSE AND ROYALTY AGREEMENTLicense and Royalty Agreement • November 8th, 2004 • Medarex Inc • Services-commercial physical & biological research • New York
This LICENSE AND ROYALTY AGREEMENT is entered into as of April 4, 2003 (the “Effective Date”) by and between PFIZER INC a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”) and MEDAREX, INC., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, and GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc., (together “Medarex”);
COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • November 8th, 2004 • Medarex Inc • Services-commercial physical & biological research • New York
This COLLABORATIVE RESEARCH AGREEMENT (“Agreement”) is entered into as of April 4, 2003 (the “Effective Date”) by and between PFIZER INC., a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and MEDAREX, INC., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, and GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc., (together “Medarex”). Each of Medarex and Pfizer is sometimes referred to herein as a “Party” and collectively as the “Parties”.
AMENDMENT #1 TO COLLABORATIVE RESEARCH AGREEMENT AND LICENSE AND ROYALTY AGREEMENTCollaborative Research Agreement • November 8th, 2004 • Medarex Inc • Services-commercial physical & biological research
This AMENDMENT #1 TO COLLABORATIVE RESEARCH AGREEMENT AND LICENSE AND ROYALTY AGREEMENT (“Amendment #1”) is entered into as of September 15, 2004 (the “Amendment #1 Effective Date”) by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 (together with its Affiliates, “Pfizer”), and MEDAREX, INC., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, and GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc. (Medarex, Inc. and GenPharm International, Inc., together, “Medarex”).
LICENSE AGREEMENTLicense Agreement • November 8th, 2004 • Medarex Inc • Services-commercial physical & biological research
THIS LICENSE AGREEMENT (the “Agreement”) is made as of September 15, 2004 (the “Effective Date”) between Pfizer Inc, a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and Medarex, Inc., a New Jersey corporation with a business address at 707 State Road, Princeton, New Jersey 08540 (“Medarex”). Pfizer and Medarex each may be referred to herein individually as a “Party” or collectively as the “Parties.”
SECURITIES PURCHASE AGREEMENT DATED AS OF SEPTEMBER 15, 2004 by and between MEDAREX, INC. and PFIZER OVERSEAS PHARMACEUTICALSSecurities Purchase Agreement • November 8th, 2004 • Medarex Inc • Services-commercial physical & biological research • New Jersey
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), is made as of September 15, 2004 (the “Effective Date”), by and between Medarex, Inc., a corporation organized and existing under the Laws of the State of New Jersey (the “Company”), and Pfizer Overseas Pharmaceuticals, a private unlimited liability company organized and existing under the laws of Ireland (the “Purchaser”).
